Cover
Vol. 1 No. 1 (2022)

Published: December 21, 2022

Pages: 17-24

Original Article

Prevalence of Multi-drug Resistance in Iraqi Patients with Tuberculosis

Haitham Mahmood Kadhim 1 Elaf Abdul-wahab 2 Rahma Hussein 1 Raghda Mazin 1
1Department of Pharmacology and Toxicology, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
2Students of Pharmacy College, Al-Nahrain University, Baghdad, Iraq
History
  • Received: October 10, 2022
  • Accepted: November 13, 2022
  • Available Online: December 21, 2022

Abstract

Objective: Tuberculosis (TB) is a bacterial, infectious disease caused by Mycobacterium Tuberculosis complex. TB causes a wide range of clinical infections affecting many parts of the body. Multi-drug resistant tuberculosis (MDR-TB) is caused by bacteria that are resistant to both isoniazid and rifampicin, the most effective anti- TB drugs, or more. MDR-TB presents a major concern in many countries and continues to threaten TB control. Methods: A retrospective cohort study carried out from 5 Jan 2020 to 30 March 2020 at the Specialized Chest and Respiratory Disease Center in Baghdad. The records of the patients who received multidrug treatment were included in the study. On the other hand, all the records that not contain full information about the socio-demographic characteristics, history of travelling or other disease, type and duration of treatment, and drug culture sensitivity excluded from the study. Results: From the 650 patients whom there records were reviewed, 130 patients had single or multi-drug resistance mainly to rifampicin and isoniazide. Comparing the presence of drug resistance according the gender showed that the number of males who had resistance to drugs was higher than that of females. Conclusion: Tuberculosis affects mainly the productive age group. It affects males more than females. Resistance to anti TB drugs was found in one fifth of patients who received treatment.

References

  1. World Health Organization. Global Tuberculosis Control: WHO Report 2013. Geneva, Switzerland: WHO; 2013.
  2. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimun OL, Arora J, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 2006;6:23.
  3. World Health Organization. Global Tuberculosis Report 2018: WHO/CDS/TB/2018.25. Geneva: WHO; 2018.
  4. Ahmed MM. Tuberculosis situation in Iraq: A puzzle of Estimates. Int J Mycobacter. 2013;2(4):248–249.
  5. WHO (2012b). Towards Achieving the Millennium Development Goals. MDG6: Combat TB, HIV/AIDS, Malaria and Other Diseases.
  6. WHO (2012a). Iraq Tuberculosis Profile. http://www.who.int/tb/country/data/profiles/en/.
  7. Tavakoli A. Incidence and prevalence of tuberculosis in Iran and neighboring countries. Zahedan J Res Med Sci. 2017;19(7):e9238.
  8. AL-Jebory I, AL-Zaag A, Asmir A. Molecular epidemiology of Mycobacterium tuberculosis isolated from pulmonary patients in Iraq. Biol Appl Environ Res. 2017;1(1):57–68.
  9. Al-Kadhimi HM, Dawood HN. The effect of age on clinical and radiological presentation in patients with pulmonary tuberculosis in Baghdad. Iraqi Acad Sci J. 2011;10(1):125–9.
  10. Lin CY, Chen TC, Lu PL, Lai CC, Yang YH, Lin WR, et al. Effects of gender and age on development of concurrent extrapulmonary tuberculosis in patients with pulmonary tuberculosis: a population based study. PLoS One. 2013;8(5):e63936.
  11. Stop TB Partnership. The Paradigm Shift: 2016-2020. Geneva, Switzerland: stoptb.org; 2015.
  12. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177:787–92.
  13. Rieder HL. Interventions for Tuberculosis Control and Elimination. Paris: International Union Against Tuberculosis and Lung Disease; 2002.
  14. Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, et al. Assessing spatial heterogeneity of MDR-TB in a high burden country. European Respiratory Journal. 2013;42(5).
  15. WHO. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018.
  16. Pyle MM. Relative number of resistant tubercle bacilli in sputum of patients before and during treatment with streptomycin. The staff meeting of Mayo Clinic. 1974:465–73.
  17. Espinal MA, et al. Standard short course chemotherapy drug-resistant tuberculosis; Treatment outcomes in 6 countries. Journal of American Medical Association. 2000:2537–45.
  18. Toman's Tuberculosis. 2nd ed. Geneva. 2004;43:198.
  19. WHO. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2019.
  20. Zhang Y. The magic bullets and tuberculosis drug targets. Ann Rev Pharmacol Toxicol. 2005;45:529–64.
  21. Jaramillo E. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Stop TB Department; 2008.
  22. The Fifth National Tuberculosis Epidemiological Survey in 2010. 2012.
  23. WHO. Anti-Tuberculosis Drug Resistance in the World. Global Project on Anti-Tuberculosis Drug Surveillance. Report 2: Prevalence Trend. Geneva: WHO; 2000.
  24. Sterne JA, Rodrigues LC, and Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2(3):200–207.
  25. Neyrolles O, and Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Medicine. 2009;6(12):e1000199.
  26. Shatha TA, and Ruqaya MA. Prevalence of tuberculosis infection among Iraqi Patients. World Journal of Pharmaceutical Research. 2018;7(1):1383–1394.
  27. AL-Marjani MF, Kadhim AA, Kadhim KA, Manki AA. Extensively drug-resistant Mycobacterium tuberculosis in Iraq. J Int Acad Res Multidisciplinary. 2013;1(11):147–155.
  28. Al-Mussawi AA. Detection of Rifampin resistance tuberculosis by GeneXpert MTB/RIF in Basra governorate/ South of Iraq. J Bio Innov. 2016;5(2):237–244.
  29. Bialvaei AZ, Asgharzadeh M, Aghazadeh M, Nourazarian M, and Kafil HS. Challenges of Tuberculosis in Iran. Jundishapur J Microbiol. 2017;10(3):e37866.
  30. Mohajeri P, Norozi B, Atashi S, and Farahani A. Anti-Tuberculosis Drug Resistance in West of Iran. J Glob Infect Dis. 2014;6(3):114–117.
  31. Goyal V, Kadam V, Narang P, and Singh V. Prevalence of drug-resistant pulmonary tuberculosis in India: Systematic review and meta-analysis. BMC Public Health. 2017;17(1):817.
  32. Muhammed W. A prevalence of drug-resistance in previously treated tuberculous patients in Baghdad. The Iraqi Postgraduate Medical Journal. 2013;12:626–632.
  33. Menon S, Dharmshale S, Chande C, et al. Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study. Lung India. 2012;29:227–31.
  34. Varghese B, Supply P, Allix-Béguec C, et al. Admixed phylogenetic distribution of drug resistant Mycobacterium tuberculosis in Saudi Arabia. PLoS One. 2013;8:e55598.
  35. Kart L, Altın R, Toret M, et al. Antituberculosis drug resistance patterns in two regions of Turkey: a retrospective analysis. Ann Clin Microbiol Antimicrob. 2002;1:6.